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Abstract
Purpose A phase I study was conducted to investigate the
safety, tolerability, and immunological responses to vacci-
nation with a combination of telomerase-derived peptides
GV1001 (hTERT: 611–626) and p540 (hTERT: 540–548)
using granulocyte–macrophage colony-stimulating factor
(GM-CSF) or tuberculin as adjuvant in patients with cuta-
neous melanoma.
Experimental design Ten patients with melanoma stages
UICC IIb-IV were vaccinated 8 times intradermally with
either 60 or 300 nmole of GV1001 and p540 peptide using
GM-CSF as adjuvant. A second group of patients received
only 300 nmole GV1001 in combination with tuberculin
PPD23 injections. HLA typing was not used as an inclusion
criterion. Peptide-speciWc immune responses were mea-
sured by delayed-type hypersensitivity (DTH) reactions, in
vitro T cell proliferation assays, and cytotoxicity (51-Chro-
mium release) assays for a selected number of clones sub-
sequently generated.
Results Vaccination was well tolerated in all patients.
Peptide-speciWc immune response measured by DTH reac-
tions and in vitro response could be induced in a dose-
dependent fashion in 7 of 10 patients. Cloned T cells from
the vaccinated patients showed proliferative responses
against both vaccine peptides GV1001 and p540. Further-
more, T cell clones were able to speciWcally lyse p540-
pulsed T2 target cells and various pulsed and unpulsed
tumor cell lines.
Conclusion These results demonstrate that immunity to
hTERT can be generated safely and eVectively in patients
with advanced melanoma and therefore encourage further
trials.
Keywords hTERT · Telomerase · Melanoma · Cytotoxic 
T cells · Vaccination · Immunotherapy
Introduction
Cutaneous melanoma is associated with a substantial mor-
tality rate and its incidence has increased signiWcantly over
the last decades [1]. Recurrence of melanoma even after
apparent complete surgical removal is frequent and implies
early existence of systemic micrometastases [2]. The con-
cept of postsurgical treatment aims at eradication of such
residual foci of disease. One strategy for such treatment of
melanoma is to stimulate the immune system with immuno-
genic tumor antigens. Vaccination with mutated oncogenic
proteins has repeatedly proven successful in inducing a
speciWc immune response in patients with malignancies
including melanoma [3, 4]. This has also been demon-
strated in vaccination studies using melanocyte-speciWc
antigens in combination with various adjuvants [5–7].
Although many studies have suggested a more favorable
course of the disease in patients with positive immunologi-
cal responses [8, 9] other trials were unable to demonstrate
a clinical beneWt despite positive immune responses to the
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far are expressed only in one or few tumor types. The
reverse transcriptase subunit of human telomerase
(hTERT), however, is a tumor-associated antigen expressed
in almost all tumors. Its expression correlates well with tel-
omerase activity: by reexpressing hTERT, tumor cells
escape cellular senescence to become immortal. hTERT,
therefore, constitutes a uniquely attractive target candidate
for cancer vaccines.
In several previous studies with patients suVering from
advanced adenocarcinoma of the pancreas [11], non-small
cell lung cancer (NSCLC) [12] or breast cancer [13]
immune responses against hTERT peptides were readily
induced and well tolerated. In all these studies, a signiWcant
association between immune responses and survival time
was observed. In contrast, a recent study using hTERT pep-
tide in combination with cyclophosphamide to vaccinate
patients with hepatocellular carcinoma failed to induce
immune responses against the peptide and also failed to
demonstrate antitumor eYcacy [14].
GV1001 is a unique peptide corresponding to a sequence
of hTERT derived from its active site. It contains the
sequence hTERT (611–626) and is capable of binding to
molecules encoded by multiple alleles of all 3 loci of HLA
class II. GV1001 can be further processed into cytotoxic T
lymphocyte (CTL) epitopes. p540 (hTERT: 540–548) is a
high-aYnity CTL epitope identical to the previously identi-
Wed HLA-A2-restricted I540 peptide [7].
The combination of intradermally applied peptide epi-
topes together with granulocyte–macrophage colony-
stimulating factor (GM-CSF) has been reported to
enhance eYcient T cell responsiveness also against mela-
noma-associated peptides in melanoma patients [3]. This
adjuvant eVect of GM-CSF is related to the maturation
and activation of dendritic cells, which after antigen
uptake will activate eVector cells [15]. Based on earlier
successful trials with other cancer vaccines [3], the aim
of combining the two hTERT peptides was to generate
both CD4+ and CD8+ tumor-reactive T cells. The pri-
mary objectives of this trial were to determine the safety
and tolerability of the hTERT peptides while applying
increasing doses of GV1001 and p540. The secondary
objective was to assess the immunological responses of
such a dual-peptide vaccine in patients with advanced
melanoma. In addition, the protocol was amended to
assess whether tuberculin could replace GM-CSF as
adjuvant for intradermal peptide vaccination. Here, we
report the successful induction of antigen-speciWc
immune responses after vaccination of melanoma
patients with intradermal hTERT peptides in combina-
tion with GM-CSF. A vaccination regimen using tuber-
culin PPD23, in contrast, did not lead to measurable
immune responses.
Materials and methods
Patient selection
During the time period August 2001–August 2002, the Wrst
ten patients were enrolled (patients #1–#10), and between
October 2003 and April 2004 the second group of patients
were enrolled (patients #11–#16), a total of 16 patients with
histologically conWrmed melanoma. The clinicopathologi-
cal variables of the Wrst and second group of patients are
summarized in Table 1. The patients were in diVerent dis-
ease stages, at least stage IB according to UICC/AJCC
2002 classiWcation. All patients, also the 7 patients with
distant metastases, were free of clinical signs of disease at
study entry and no patient showed disease progression
under vaccination. The Karnofsky performance status of all
patients was 80 or higher. Only patients of 18 years or
more, for whom at that time standard therapy of interferon
or chemotherapy had previously been evaluated were
included. HLA typing was not used as an inclusion crite-
rion since the vaccine peptides are postulated to be promis-
cuous (see below and [12]). Patients with signiWcant lung,
heart or infectious diseases as well as patients testing posi-
tive for hepatitis virus or HIV were excluded. Further
exclusion criteria were: elevated blood values for transami-
nases and creatinine, chemotherapy or radiation therapy
within 4 weeks prior to vaccination, the concomitant treat-
ment with medication possibly aVecting immunocompe-
tence (i.e., systemic corticosteroids) as well as pregnancy,
breast-feeding or insuYcient contraception for fertile
patients. Recruitment of patients in the Wrst group started
29.8.01 and ended 28.8.02. Patients in the second group,
where tuberculin was used as adjuvant, were recruited
between 31.10.2003 and 19.04.2004.
Vaccine and control peptides
The telomerase peptide vaccines GV1001 (also called
p611) and p540 were provided by GemVax AS, Porsgrunn,
Norway. The vaccine GV1001 consists of a synthetic pep-
tide corresponding to the 16 amino acid residue 611–626
fragments (EARPALLTSRLRFIPK) of the hTERT protein.
The vaccine p540 consists of a synthetic peptide corre-
sponding to the 9 amino acid residue 540–548 fragments
(ILAKFLHWL) of the hTERT protein. p540 is a well-
known HLA-A2 epitope [12, 16], but predictions (http://
syfpeithi.de) and own data (unpublished) indicate that this
peptide also may be presented by many other HLA class I
molecules. Both peptides were produced by Avecia Bio-
technology (Cheshire, England). The Wnished products,
GV1001 and p540 were manufactured by Isopharma AS
(Kjeller, Norway), supplied in vials as freeze-dried products,
and released for clinical use by GemVax AS (Porsgrunn,123
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Two peptides, one derived from telomerase, Pep 544
(hTERT 548–566), and one derived from mutant p21 RAS,
Pep 508; (KRAS 52–70, Q61H), served as negative con-
trols in the T cell proliferation assays were used to monitor
T cell responses in blood samples from the vaccinated
patients. The control peptides were supplied as lyophilized
powder by The Corporate Research Center Norsk Hydro
(Porsgrunn, Norway). Prior to patient administration the
peptides were dissolved in sterile saline to achieve the dilu-
tion required.
Recombinant hTERT
Recombinant hTERT (563–735) was cloned in frame with
the N-terminal 6x His tag in E. coli expression vector
pET28b(+) (Novagen, Darmstadt, Germany). The protein
was produced in E. coli BL21 Codon Plus (DE3)-RIPL
(Stratagene, La Jolla, CA, USA), puriWed by using NiNTA
chromatography under denaturing conditions (Qiagen, Hil-
den, Germany) and tested by Western blot analysis with
anti-His antibodies (Qiagen) and Rabbit Anti-Mouse Ig
HRP (DakoCytomation, Glostrup, Denmark). The fraction
of interest was dialyzed in Slide-A-Lyzer® Dialysis Casette
10,000 MWCO (Pierce, Rockford, IL, USA) against MQ-
water and sterile-Wltered before use.
Vaccination protocol
The treatment protocol was approved by the Medical Ethics
Committee of the Canton of Berne, Switzerland, and
studies were performed according to the principles of the
Helsinki declaration. Written informed consent from all
patients was obtained before inclusion into the study.
Table 1 Patients’ characteristics, T cell response, and survival time: (A) Two peptides (p540 and GV1001) and GM-CSF group, (B) One peptide
(GV1001) and PPD23 group
pos erythema and inWltration > 5 mm, neg erythema and inWltration < 5 mm, PPD ! hTERT Tuberculin PPD23 was injected 2 days prior to
hTERT peptide, PPD + hTERT Tuberculin PPD23 was injected together with hTERT peptide, ND not done, LD low dose, HD high dose, w6 week
6, w10 week 10, SI stimulation index (cpm with antigen/cpm without antigen) was determined after 2 cycles of in vitro stimulation with APCs and
antigen as described in “Materials and methods”. An SI of more than 2.0 was considered positive. Survival time is reported in months from begin-
ning of the vaccination
Pat.# (sex/age) Stage 
(AJCC)
Peptide 
dosage
Injection 
site
DTH Proliferation assay [SI] Cytotoxicity assay Survival 
(months)
GV1001
+ p540
w6, GV
1001
w10, GV
1001
w6, p540 w 10, p540 p540 GV1001 HLA-A02
(A) Two peptides and GM-CSF group
1 (M/62) IV LD Thigh Pos 1.0 1.2 1.0 1.2 Neg ND Pos 37
2 (M/66) IV LD Thigh Neg 1.0 ND 0.85 ND Neg ND ND 11
3 (M/56) IIIB LD Thigh Neg 1.1 1.9 ND ND ND ND ND 64
4 (M/53) IV HD Thigh Pos 3.4 2.6 1.34 1.3 63%, w10 Pos Pos 44
5 (F/51) IIIB HD Arm Neg 1.2 1.8 0.93 1.2 ND ND ND 52
6 (F/40) IV HD Arm Neg 2.1 2.2 0.81 0.9 ND Pos ND 44
7 (M/67) IIB HD Arm Neg 3.0 9.2 1.34 5.0 39% ND Pos >90
8 (M/45) IV HD Thigh Pos 2.7 2.8 1.0 0.9 ND Neg ND 6
9 (M/74) IIIA HD Thigh Neg 26.2 2.6 1.0 0.9 18% Pos Neg 8
10 (M/58) IIIB HD Thigh Neg 3.3 2.5 0.62 0.9 ND Neg Pos 40
Pat.# 
(sex/age)
Stage 
(AJCC)
Strategy Injection 
site
DTH DTH Proliferation assay Survival 
(months)
PPD23 GV1001 GV1001
B: One peptide and PPD23 group
11 (F/34) IB PPD ! hTERT Thigh Pos Neg Neg >90
12 (F/60) IIIA PPD ! hTERT Thigh Pos Neg Neg >90
PPD + hTERT Thigh Pos Neg Neg
13 (F/32) IV PPD + hTERT Thigh Pos Neg Neg 16
14 (M/58) IV PPD + hTERT Thigh Pos Neg ND 11
15 (F/53) IIIA PPD + hTERT Thigh Pos Neg ND >90
16 (M/43) IIIB PPD + hTERT Thigh Pos Neg ND 27123
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performed: (1) Physical examination including medical his-
tory and assessment of ECOG performance status. (2)
Hematological testing for hemoglobin, hematocrit, erythro-
cyte sedimentation rate, white blood cell and platelet count
and blood chemistry panel. (3) White blood cells were iso-
lated and tested in vitro for general immunocompetence
and pre-vaccination T cell reactivity against the vaccine
peptides (methods described below).
Eligible patients (#1–#10) received 8 vaccinations, each
consisting of a combination of the two hTERT peptides
over a period of 10 weeks (Table 1A). The Wrst three
patients received 60 nmole (112 g) GV1001 and 60 nmole
(68.4 g) p540. After reviewing the safety data for these
three patients, the doses were adjusted such that the follow-
ing seven patients received 300 nmole (560 g) of GV1001
and 300 nmole (342 g) of p540 per immunization. These
dose levels were selected based on previous experience
with the same vaccine in patients with pancreatic cancer
(8). The vaccine was administered by intra-dermal (i.d.)
injection on days 1, 3, 5, 7, 14, 21, 35, and 63. Between 5
and 15 min before the vaccination, i.d. injections of 30 g
recombinant human GM-CSF (Leucomax; Schering–
Plough, Cork, Ireland) were given either in the proximal
ventral thigh region or the proximal arm region (in patients
with a history of melanoma on the lower extremities), fol-
lowed by i.d. administration of hTERT peptide at the same
site. This amount of GM-CSF has been chosen as it has
been successfully used in former trials [4, 11, 12]. Patients
in the second group (#11–#16) were immunized using
PPD23 (Tuberkulin PPD RT 23, Pro Vaccine, Zug, Swit-
zerland) as adjuvant. 0.1 ml PPD23 solution containing 2
tuberculin units (0.4 g) was injected 2 days prior to the
hTERT peptide (GV1001 only, high dose, i.e., 300 nmole
(560 g)) at the same vaccination site, or was administered
together with the peptide (Table 1B). Two tuberculin units
PPD23 were used as this is the recommended amount for
the induction of a skin reaction. One patient (patient #12)
was vaccinated with both regimens in succession. As a pre-
vious study using the same two peptides for vaccination
[12] showed positive in vitro tests against p540 for only 8%
of the patients, and as none of the Wrst 10 patients in this
study developed a positive DTH reaction against p540, the
second set of patients was only vaccinated with the longer
GV1001 peptide.
The vaccination site was marked, in order to place every
vaccine precisely at the same site. Comprehensive immuno-
logical testing, assessment of adverse drug reactions, physi-
cal examination, and assessment of performance status
were done at each vaccination visit. Blood screening took
place in 6 of these visits. At the follow-up visit on day 77, a
complete clinical screening identical to the initial workup
was performed, as well as a blood screening.
Delayed-type hypersensitivity
Delayed-type hypersensitivity (DTH) skin tests were per-
formed with both peptides at vaccinations 1, 4–8. Sixty
nanomoles of the single peptides dissolved in saline were
injected i.d. at separate sites (5–7 cm apart from each other)
and contralaterally to the vaccination site. A positive skin
reaction was deWned as erythema and induration, average
diameter ¸ 5 mm, 48 h after i.d. injection. The patients
were instructed to measure the diameter of the DTH reac-
tion and report it to the clinician, whenever a direct evalua-
tion by the clinician was not possible. The clinician
recorded the skin test as positive or negative in the clinical
report form.
Cells
Prior to vaccination on each visit (except visits 2 and 3),
50 ml ACD blood was drawn to assess in vitro proliferative
T cell responses against GV1001 and p540. Peripheral
blood mononuclear cells (PBMCs) were isolated from
peripheral blood by density-centrifugation over Ficoll–
Hypaque (Lymphoprep; Nycomed, Oslo, Norway) and
were washed and frozen immediately in RPMI-1640
(Gibco, Paisley, UK) with 20% FCS (PAA Laboratories
GmbH, Paching, Austria) and 10% DMSO and stored at
<¡70°C in liquid N2. Due to high background proliferation
with cells frozen in FCS, 10% human albumin was substi-
tuted for FCS during freezing of blood samples from 2002
on. All assays were done with thawed samples.
Proliferation assay
As in former studies ex vivo proliferation was not enough
sensitive to demonstrate peptide-speciWc T cell responses
[4, 11, 12], a secondary stimulation assay was used, essen-
tially as described earlier [17]. BrieXy, thawed PBMC were
seeded at 2 £ 106 per well in 24-well plates (Costar, Cam-
bridge, MA, USA) in 1 ml of X-VIVO10 (Bio–Whittacker
Inc., Walkersville, MD, USA) containing 15% heat-inacti-
vated human serum and antibiotics supplemented with
GV1001 or control peptides at 25 mM concentration. After
3 days of culture, the medium was supplemented with 10 U
per ml of recombinant human interleukin-2 (Amersham,
Aylesbury, UK). Cultured cells were restimulated for one
more cycle after 7–9 days of culture using irradiated
(30 Gy) PBMC as antigen presenting cells and the same
peptide concentration as above. The pre-stimulated cells
were tested on days 14–18 for speciWc proliferating capac-
ity against GV1001 and control peptides at 25 mM concen-
tration, by using 5 £ 104 T cells and autologous, irradiated
(30 Gy) PBMCs (5 £ 104 cells per well) as antigen present-
ing cells (APCs). After 2 days, wells were pulsed with123
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ues are given as stimulation index (SI). SI was calculated as
mean counts per minute (cpm) from triplicate wells with
antigen divided by mean cpm without antigen. A SI above
2 was considered as positive.
As a measure of general immunocompetence, the T cell
response to puriWed protein derivative (PPD) of tuberculin
and staphylococcal enterotoxin C (SEC) was measured in
blood samples taken at inclusion. All patients demonstrated
responses within the normal range, and there was no corre-
lation between the response to these antigens and the subse-
quent response to the vaccine peptides.
Cytotoxicity assay
The cytotoxicity assays were performed essentially as
described earlier [17], using peptide-pulsed, 51Cr-labeled
tumor cells, T2 cells or EBV-transformed cells as targets.
The cell lines T2 (HLA A2+, antigen processing defective),
K562 (NK sensitive leukemia), LnCAP (prostate cancer),
Panc-1 (pancreatic canrcinoma), LS174 (colon cancer)
were obtained from the American Type Culture Collection
(ATCC, http://www.attc.org). The melanoma cell lines
FM-3, FM-6, FM-60, and FM-48 were obtained from The
European Searchable Tumor Line Database (ESTDAB,
http://www.ebi.ac.uk/ipd/estdab/). Unless otherwise stated,
the peptide concentration used for pulsing was 1 gM.
Maximum and spontaneous 51Cr release of target cells was
measured after incubation with 5% Triton X-100 (Sigma)
or medium, respectively. SpeciWc cytotoxicity was calcu-
lated according to the formula: (experimental release ¡
spontaneous release)/(maximum release ¡ spontaneous
release) £ 100.
Cytokine production
Cytokine production by T cell clones was measured in
supernatants taken from T cell assays 24 h after peptide
stimulation, using a human 17-plex cytokine kit and the
Bio–Plex instrument (BioRad Laboratories Inc., USA), as
described by the manufacturer.
Flow cytometry
Flow cytometric analysis was performed according to stan-
dard protocol. PE-labeled HLA-A*0201 presenting the
hTERT peptide p540 or as a control the tax peptide, was
provided by Proimmune (Oxford Science, Oxford, UK).
Cellular staining was performed according to the manufac-
turer indications. PerCP-labeled anti-CD8 mAb (BD Bio-
sciences) was used to stain CD8 T cells. Samples were
analyzed on a FACScan (BD Biosciences) using CellQuest
software.
T cell lines and clones
Cultures that showed a proliferative response against p540
were subsequently tested for cytotoxicity using chromium-
labeled T2 cells pulsed with hTERT peptide (p540) as
targets, and the PBMC from the patients were typed for
HLA-A2 only. Cell lines were derived by repeated peptide
stimulations and CTLs were cloned from the proliferative
bulk cultures by limiting dilution using allogeneic PBMC as
feeder cells and PHA as stimulator essentially as described
[17]. CD4 positive clones were similarly cloned from
proliferative bulk cultures responding to GV1001 using the
same procedure.
Toxicity and safety
Adverse events were evaluated at each visit. The clinical
investigator graded the events as probable, suspected,
unlikely or not related to the treatment. Adverse events
were considered related to the treatment if the relationship
was reported as probable or suspected.
Results
Safety and tolerability
The vaccination with the two hTERT peptides was well tol-
erated in all 10 patients that received the vaccine in combi-
nation with GM-CSF as adjuvant, as well as in those 6
patients receiving only GV1001 in combination with tuber-
culin as adjuvant. In the GM-CSF group, occasionally, a
slight swelling and erythema around the vaccination site
occurred, lasting 3–5 days, thereafter resolving completely.
An eczematous reaction at the vaccination site was
observed in three patients, with a peak of extension and
intensity approximately 48 h after injection, resolving com-
pletely within a few days. These local skin reactions were
accompanied by only minor subjective discomfort and were
rated as favorable local eVects in terms of markers of
immunological response. In the tuberculin group, an inWl-
tration of 1–2 cm occurred in the all patients. No clinically
important signs of adverse events as well as other signs of
toxicity occurred. No clinical signs of auto-immune disease
nor abnormal biochemical or hematological parameters
related to the vaccines were observed.
Characterization of immune responses against GV1001 
and p540
Patients with a positive DTH test or the presence of p540 or
GV1001-speciWc T cells in peripheral blood after vaccina-
tion were considered as immune responders. An example of123
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rizes immune response of all patients. In the Wrst group of
patients, vaccination was performed with the two hTERT
peptides p540 and GV1001 in two diVerent dosages
(Table 1A). The Wrst three patients were vaccinated with
the hTERT peptides in low dose (60 nmole). One of these 3
patients (patient #1) showed a positive DTH reaction. In
none of these patients, a peptide-speciWc immune response
could be detected by in vitro T cell assays. Based on this
observation, the dosage of both peptides was increased to
300 nmole. With this vaccination regimen, 2 of 7 patients
showed a positive DTH reaction for GV1001 (patient # 4
and #9) and 6 of these 7 patients showed positive in vitro T
cell immune responses. Taken together, 7 of these 10
patients showed a positive immunological response to the
vaccine peptides, either as a positive DTH reaction or as
positive in vitro T cell response. A strong positive response
against p540 was detected by the cytotoxicity assay in
patient #4 and #7 (see below), and some cytotoxicity was
also observed in patient # 9.
In the second group of 6 patients (Table 1B), a new
immunization strategy with tuberculin (PPD23) as adjuvant
was applied. As the immune response to p540 was low in
the Wrst group and in a study with patients with non-small
lung cancer [12], this patient group was only vaccinated
with the longer hTERT peptide GV1001. Despite the fact
that PPD23 was very eYcient in inducing a skin inXamma-
tion (DTH) in all six patients, none of these patients
showed positive in vitro T cell assays.
Detailed analysis of T cell responses to hTERT in two 
patients
In two patients (patients #4 and #7), a more detailed analy-
sis of T cell responses was performed. Both patients
responded to GV1001 and p540 in proliferative assays. In
order to study the p540 reactive cells, we produced HLA-
A2 pentamers with p540. Frozen samples of cells harvested
before vaccination and 6 weeks after vaccination, assayed
ex vivo without prior stimulation, showed no evidence of
expansion of hTERT-positive cells (data not shown). On
the other hand, in vitro stimulation for 11 days with p540
revealed the presence of p540 A2 pentamer positive T cells
in the blood sample harvested on week 6 after the vaccina-
tions began (Fig. 2a). After 11 days of in vitro stimulation,
15.5% pentamer positive cells were seen in the post-vac-
cine sample versus 0% in the parallel culture of pre-vaccine
cells, clearly demonstrating an enhanced precursor fre-
quency following vaccination. Control experiments with
HLA2/Tax pentamers showed no increase in positive cells.
In order to investigate if these cells were also function-
ally active, we tested the capacity of bulk cultures gener-
ated from PBMC’s harvested at diVerent time points after
vaccination to kill p540-pulsed T2 cells in a conventional
chromium release assay. The bulk cultures were generated
by in vitro stimulation with the two vaccine peptides.
Figure 2b clearly demonstrates that the cells were capable
of speciWcally killing p540 pulsed targets. Little or no kill-
ing was seen with unpulsed T2 targets. Importantly, killing
increased with repeated vaccinations indicating a boosting
eVect of vaccination. Interestingly, a parallel increase in
intrinsic activity against T2 cells pulsed with a peptide mix-
ture consisting of all 8 overlapping 9-mers derived from
GV1001 was also observed, indicating that CTLs against
one or more fragments of GV1001 were generated in paral-
lel with generation of T helper activity. We next generated
a cell line by repeated stimulation of PBMCs harvested on
week 6 and tested this cell line against p540-pulsed T2 tar-
get cells and HLA A2 positive and A2 negative cell lines.
The results are shown in Fig. 2c and d. The cell line
eYciently killed peptide-pulsed T2 targets even at low
eVector/target (E/T) ratios. No killing of the HLA-A2 nega-
tive melanoma cell line FM48 was observed, neither in the
absence nor presence of p540. The A2 positive melanoma
cell line FM-3, pulsed with the peptide p540, was killed by
the cell line. Interestingly, there was also low level killing
of unpulsed FM-3 cells. These results indicated that p540
speciWc CTLs with the capacity to kill melanoma targets
were generated during vaccination.
To provide further evidence for this, we generated spe-
ciWc T lymphocyte clones (TLCs) from the cell line by lim-
iting dilution. Data from three of these clones are given in
Fig. 3. Figure 3a shows that all TLCs eYciently killed
p540-pulsed T2 targets and no killing was seen with
Fig. 1 Skin reaction in patient 
#8 48 h after vaccination: a mix-
ture of both peptides GV1001 
and p540 was injected intrader-
mally on both tights, on the left 
side GM-CSF was injected 
15 min prior to peptide-injection 
at the same site. Positive reac-
tions could been induced at the 
DTH (a, right tight) and vacci-
nation site (b, left tight)123
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described to exert natural killer (NK) cell activity [18], we
incubated our TLCs with increasing numbers of K562 cells,
indicating that killing was not due to NK cell activity. A
representative dose–response experiment with clone #26 is
shown in Fig. 3b. With doses between 10 nM and 10 M
peptide, eYcient killing was seen even with very low E/T
ratio’s (1.25:1). Below the 1 nM threshold, a sharp drop in
cytolytic activity was observed. These results indicate that
high-aYnity TLCs had been generated by vaccination. We
therefore wanted to investigate if the TLC #26 was able to
lyse tumor cell lines without exogenous addition of peptide
in a dose-dependent manner. These results are shown in
Fig. 3c.
TLC #26 killed the cell lines FM-3, Panc-1, LnCAP, and
FM-60 in a dose-dependent fashion. Control cell lines
including the HLA-A2 negative cells LS174 and FM-48,
and the HLA-A2 positive cell line FM-6 showed background
Fig. 2 SpeciWc CTL responses 
against the vaccine peptides 
p540 and GV1001 in patient #4. 
a Pentamer staining of PBMCs 
before, i.e., at baseline, (upper 
panel) and after (lower panel) 
vaccination. The two right 
graphs represent staining with 
the HLA-A2/hTERT (p540) 
pentamers and the left graphs 
depict staining with HLA-A2/
Tax pentamers (control). Cells 
were also stained for CD8. 
b SpeciWc killing of T2 target 
cells pulsed either with p540 or a 
mixture of 8 diVerent, overlap-
ping nonapeptides covering the 
whole GV1001 amino acid se-
quence. EVector cells in this as-
say were harvested following the 
4th, 6th, and 10th vaccinations 
and expanded by two cycles of 
in vitro stimulation by p540 and 
GV1001 peptides. Standard 
chromium release assay. T2 
without peptide served as a neg-
ative control. c Dose–response 
curve for p540-speciWc CTL ly-
sis by eVector cells obtained 
from the blood sample harvested 
at week 6 and expanded as a cell 
line by additional rounds of pep-
tide stimulation in vitro. 
d Cytotoxicity of the same cell 
line tested with p540-pulsed or 
unpulsed melanoma cell lines 
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1560 Cancer Immunol Immunother (2011) 60:1553–1564killing. Killing to some extent reXected the inherent telo-
merase enzymatic activity in the cell lines, as FM3 had
very high telomerase activity in the TRAP assay (data not
shown). When the same cell lines were pulsed with p540
and tested with the same E/T ratios of T cells (Fig. 3d),
increased killing was seen within a broad range of E/T
ratios. Furthermore, pulsed FM-6 cells were also killed,
indicating that insuYcient generation of endogenous pep-
tide by processing hTERT in this cell line occurred. All cell
lines were less susceptible to killing than T2 following
pulsing.
Patient #7 generated an immune response against both
vaccine peptides. We generated both CD4 and CD8 T cell
clones for further characterization of this patient’s T cell
responses. Out of 40 T cell clones screened, 22 were vac-
cine peptide-speciWc. Of these, 20 were reactive with p540
and two with GV1001 in proliferative testing (data not
shown). The p540 bias was due to removal of the majority
of CD4 cells by depletion with anti-CD4 coated Dynabe-
ads® prior to cloning. In the initial screening, PBMCs were
used as antigen presenting cells (APCs) in the assay. To
study the CTL activity of the p540 reactive clones, we
selected some clones for peptide-pulsing studies. Three out
of Wve clones were able to kill target cells in a cytolytic
assay (Fig. 4a), but the experiment revealed some striking
diVerences. TLCs #4, #6, and #127 eYciently killed pep-
tide-pulsed autologous PHA blasts. In addition, clones #4
and #6 killed peptide-pulsed T2 cells. On the other hand,
clones #7 and #20 which both proliferated to p540 in the
initial screening were unable to kill both targets.
To try to explain this discrepancy, we went back and
tested these clones and an additional clone (TLC #14 from
patient #7) with peptide-pulsed T2 cells as well as autolo-
gous PBMCs as APCs in the proliferative assay. The corre-
sponding data are shown in Fig. 4b. These results conWrm
that all cell lines proliferate speciWcally when recognizing
p540-pulsed PBMCs. The two T cell clones that did not kill
peptide-pulsed T2 cells failed to proliferate when con-
fronted with T2 cells pulsed with p540. The same clones
proliferated vigorously upon recognition of PBMC pulsed
with p540. The same pattern was seen for TLC#14. Taken
together, these experiments indicate that the three T cell
Fig. 3 SpeciWc killing by CTL clones from patient #4. a SpeciWc lysis
of p540-loaded T2 target cells by three CTL clones (TLC#26, 45, 46)
at E/T ratio of 20:1 in the presence of increasing ratios of K562 cells
(NK cell target). b Dose–response curve for a representative CTL
clone (#26). T2 cells were loaded with the indicated concentrations of
p540. c and d Lysis of various tumor cell lines by TLC #26 (c) without
addition of exogenous peptide and d with addition of exogenous p540
peptide
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this peptide presented on class I molecules which are pres-
ent on autologous APCs but not on T2 cells.
To address this possibility, we tested the proliferation of
TLC #7 against p540-pulsed APCs from a limited panel of
donors (Fig. 4c). The patient was HLA A2/A23 (B7/5703/
C7) positive and the other donors shared A2 or A23 with
the patient. TLC #7 responded vigorously to APCs from all
donors pulsed with p540. The response was speciWc as no
other response was observed in the absence of peptide.
Moreover, the T cell clone did not present the peptide to
itself, since proliferative response was absolutely depen-
dent on PBMCs. The response against the two A2 contain-
ing pulsed PBMCs was more pronounced than the response
against the A23 positive-pulsed PBMCs. Another feature
which became obvious from this experiment was that high
concentrations of the peptides was required, since the
responses dropped abruptly to background levels when
reduced from 10 to 1 M. Taken together, these results
indicate that some type of low aYnity interaction between
peptide and several diVerent HLA molecules may take
place, and that this is suYcient to generate a very vigorous
proliferative response in this type of T cell clone. The phe-
notype of the T cell clones in Fig. 4b was investigated by
Xow cytometry. TLCs #4, #6, #7, #14, and #20 all had the
conventional CTL phenotype (CD3+, CD8+, CD4¡). The
TLC #127 turned out to be double negative (CD3+, CD8¡,
CD4¡). The peptide/dose response curve indicated that the
aYnity of this CTL clone was in the same range or even
higher as that of the CD8+ clones, such as TLC #6
(Fig. 4d).
In a further step, we generated CD4+ T cell clones from
patients #4 and #7. Some data are given in Fig. 4e, which
depicts results with two T cell clones derived from patient
#7 (#6–25 and #6–32). Both clones are CD3+, CD4+,
CD8¡ and are HLA-DR restricted (data not shown). Both
T cell clones proliferated vigorously and speciWcally
against GV1001-pulsed APCs. Since hTERT may be pro-
cessed to peptides in many diVerent ways, and the binding
motifs of diVerent class II molecules are diVerent, it was
important to investigate if these T cell clones also were
capable of recognizing hTERT fragments generated by
feeding recombinant hTERT to APCs. The two HLA-DR
restricted T cell clones both recognized autologous PBMCs
that were pulsed with recombinant telomerase protein,
strongly suggesting that natural processing of hTERT may
give rise to peptide fragments, Wtting into the HLA-DR
molecules used for presentation to the two clones.
To characterize the T cell response further, we also
investigated the cytokine production by the T cell clones.
Fig. 4 Analysis of CTL activity and proliferative responses of TLCs
from patient #7. a SpeciWc lysis of either unpulsed or p540-pulsed T2
cells and autologous PHA blasts. b Proliferative responses (cpm) of
the indicated TLCs using T2 and PBMCs as APCs with or without pep-
tide (p540). c Proliferative response of TLC #7 using PBMCs from
diVerent donors as APCs. The patient was HLA A2/A23 (B7/5703/C7)
positive and the other donors shared A2 or A23 with the patient.
d Proliferative response of TLC #6 (CD8+) and #127 (double nega-
tive) to diVerent peptide concentrations. e Proliferative responses of 2
TLCs against recombinant hTERT and GV1001. The TLCs were incu-
bated with APCs and the indicated concentrations of either recombi-
nant hTERT or GV1001. cpm was measured in a standard 3-day
proliferation assay used for TLCs
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as APCs and peptide (GV1001) or CD3 and CD28, two
TLC from patient #7 produced substantial amounts of IL-4,
one of them also with high amounts of IL-10. All other
investigated TLCs produced, however, a predominantly
Th1 cytokine proWle with high amounts of IFN- and
TNF- as well as very high amounts of GM-CSF (data not
shown).
Discussion
In this study, we report the clinical testing of an anticancer
vaccine based on two diVerent telomerase-speciWc peptide
epitopes in patients suVering from high risk melanoma. Our
results conWrm that hTERT peptides and GM-CSF as adju-
vant is well tolerated as already described in patients with
lung cancer [19], and pancreatic carcinoma [11].
A positive DTH reaction could be detected in 3 of 10
patients vaccinated with GM-CSF as adjuvant. Notably,
all patients with positive DTH reaction had received their
vaccination in the thigh and not in the arms, conWrming
earlier observations [3]. Patients suVering from pancre-
atic cancer vaccinated with the same regimen [11]
showed a similar response rate, (36%). These results are
lower than those reported in patients suVering from lung
cancer given the same vaccine [19], where 59% of vacci-
nated patients had a positive DTH. Seven of the 10 vacci-
nated patients showed either a positive DTH or a positive
in vitro assay. Interestingly, this ratio was higher (6 of 7)
in the high dose regimen group than in the low dose
group (1 of 3). It has been shown that the dosage of the
peptide is crucial for the induction of a strong immune
response. There seems to be an optimal dosage for
GV1001 in the range of 0.5–1.0 mgs. There is evidence
that higher doses result in a lower rate of positive reac-
tions [11], indicating a bell-shaped curve. This is also
observed at the clonal level (Fig. 4d) [19]. An improve-
ment of the vaccination regimen is therefore not possible
by increasing the dosage of the peptide. One strategy is to
look for a better or stronger adjuvant. Incomplete Fre-
und’s adjuvant either alone or in combination with TLR
agonists have been used by diVerent investigators [20]. In
this study, we used PPD23, a protein compound of myco-
bacteria which induces a strong DTH reaction in BCG
vaccinated patients when injected intradermally, creating
a pro-inXammatory environment. Surprisingly, this adju-
vant could not induce an anti-hTERT immune response,
either by simultaneous injection or if injected 2 days
before injection of the peptide. One may speculate that
the immune response against the bacterial peptides is
dominant, resulting in a suppression of the immune
response against the hTERT peptide.
One intriguing result is that there is no correlation of the
immune response assessed by the diVerent assays.
Although patient #1 had a positive DTH skin reaction, all in
vitro assays were negative. On the other hand, patient #7
showed strong in vitro immune responses, but the DTH
skin reaction was negative. This observed discrepancy
between the skin tests and the in vitro tests has been
observed earlier [11]. It might either reXect diVerent sensi-
tivities in the two assays or be a result of biologically diVer-
ent immune reactions being generated. Thus, a shift in
cytokine production away from classical inXammatory
cytokines might result in a lack of DTH reaction. The anal-
ysis of the cytokine production of our T cell clones revealed
that at least some TLC produced high amounts of IL-4 or
even IL-10. A diVerence in the balance of the diVerent
clones produced in diVerent patients may possibly explain
some of these discrepant results.
Cytotoxicity assays with p540 was positive in 3 of the 5
tested patients (Table 1). All positive tested patients were
vaccinated with the higher dose of the two peptides. Inter-
estingly, patient #9 was HLA-A02 negative providing fur-
ther evidence that p540 is presented by other class I alleles
that A02 as has been postulated earlier [12]. The CTL
response increased with increasing number of injections of
the vaccine, demonstrating a boosting eVect of repeated
vaccinations as has been previously shown by others [8].
This underlines the importance of the concept of multiple
injections. Brunsvig and coworkers [19] could induce sta-
ble high levels of immunity over the time period of over
6 months with repeated booster injections. Remarkably,
the induction of a CTL response against the HLA class
I-restricted peptide p540 was paralleled by a CTL response
against the cocktail of all eight possible nonapeptides of the
longer GV1001 peptide. This indicates that the longer
GV1001 peptide has been processed and presented on
MHC class I molecules to CD8 T cells, providing indirect
evidence for cross-presentation.
The eYcacy of a T cell response seems to be dependent
on the frequency of the T cells and the aYnity of the T cell
receptor [21]. The Wnding that the T cell responses are only
detectable after 2 cycles of pre-stimulation may explain the
poor clinical eVect of the vaccination protocol. On the other
hand, the correlation of the aYnity with the eVectiveness is
less well documented but recent data [22] indicate that an
optimal range has to be achieved to get an eYcient T cell
response. As shown in Fig. 3b, high-aYnity T cells were
detected in our in vitro experiments. It remains, however,
diYcult to make any conclusion about the aYnity of the T
cells in vivo as we only assessed few clones which might
have been selected by the in vitro conditions.
Upon contact with peptide antigen, CTLs have been
described to produce the Th1 cytokines IFN- and TNF-
[23, 24]. In this study, the two investigated CTL clones123
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cytokines upon antigen-speciWc stimulation. In addition,
both clones also produced IL-6, IL-8, and GM-CSF. Sur-
prisingly, also the Th2-related cytokines IL-4 and IL-10
were produced. Especially IL-10 is a potent inhibitory cyto-
kine and has been shown to be produced by regulatory T
cells [25]. Such mixed cytokine proWles have been
observed in T cell clones from many diVerent patients who
have been treated with cancer vaccines [8]. Since these T
cell clones produce multiple cytokines with partly opposing
activities, it is diYcult to speculate what the overall out-
come will be in vivo.
Although the number of patients included in this study is
rather low, these data show that tumor-speciWc immune
responses against hTERT peptides can easily be induced in
most melanoma patients. The correlation of a strong
immune response with long-term survival has been docu-
mented earlier [11, 26]. The here observed survival times
(Table 1) are mainly dependent on the stage of the disease.
Interestingly, the long time survivor patient #7 showed a
strong in vitro immune response, but he also had compared
to the other patients an early stage of the disease. Because
of the small number of patients in diVerent disease stages, it
is not possible to draw conclusions about the clinical
eYcacy of the vaccination protocol. Controlled trials will
be needed to answer this question. The fact that the immu-
nological responses were only detectable after in vitro
expansion of the T cells may indicate that the aim of further
studies must focus on the search of more potent vaccination
strategy. This may either be achieved by eliminating immu-
nosuppressive mechanisms [27], enhancing the immune
response by a more potent adjuvant or by continued booster
vaccination as have been used in other trials [19].
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